For around 20 years, Avi Veidman spent his days in the Israeli intelligence community, analyzing satellite images.
That was until 2017, when he founded a startup called Nucleai. Now, he’s scouring biopsy samples for cancer cells.
Nucleai’s technology is not searching out signs of danger. Instead, the company’s technology maps the proximity of cancer cells, healthy cells, and proteins. Then, it uses artificial intelligence models to identify patterns between those biological elements and historical clinical data to determine which patients are most likely to respond to treatments and should therefore be enrolled in drug companies’ trials.
Click this link for the original source of this article.
Author: Allison DeAngelis
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.